Waters Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WAT research report →
Range $400 – $535
Price Chart
About the company
Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems.
- CEO
- Udit Batra
- IPO
- 1995
- Employees
- 15,000
- HQ
- Milford, MA, US
AI snapshot
Six angles, distilled from the data.
The stock remains in a long-term uptrend, trading well above its 200-day average of 374.4 and not far from its 52-week high of 483.33. That keeps the regime constructive, though the recent pullback from the upper end of the range shows momentum can cool after extended strength.
Street sentiment stays constructive: consensus is Buy with a 470 target, above the last close and below the high-end 535 call. Recent revisions have leaned positive, with multiple target raises in October and November and only one downgrade-style move to Hold from an existing Outperform.
Waters has a strong beat streak, with 8 straight EPS beats and the latest quarter topping estimates by 2.8%. The forward bar is rising sharply, with next-year EPS estimates at 16.53, so shareholders should watch whether management can support that step-up with sustained demand and margin discipline.
No notable discretionary insider buying or selling. Recent activity is dominated by award grants and administrative entries, including officer and director awards, which are not the same as open-market conviction trades.
Profitability is solid but not flashy: gross margin is 55.4% and operating margin is 15.99%, while net margin is 1.76%. Growth is mixed, with revenue up 120.9% year over year but earnings growth down 67%, and the balance sheet carries $903.3 million of net debt.
Waters wins on premium margins and a durable installed-base consumables model, but it is not a cheap name at 32.2 times earnings. The setup favors a quality premium versus peers, with the market paying for execution rather than a discount valuation.
Similar companies
Peers in the same neighborhood.
- Market Cap
- $43.29B
- P/E
- 194.25
- Fwd P/E
- 30.01
- PEG
- -2.48
- P/S
- 8.00
- P/B
- 2.93
- EV/EBITDA
- 44.11
- Div Yield
- 0.00%
- Gross Margin
- 49.66%
- Op Margin
- 4.73%
- Net Margin
- 1.75%
- ROE
- 0.81%
- ROIC
- 1.06%
Latest fiscal year · YoY change
- Revenue
- $3.17B+7.0%
- Gross Profit
- $1.88B+6.7%
- Op Income
- $802.59M
- Net Income
- $642.63M+0.8%
- EPS
- $10.80+0.5%
- OCF Growth
- -14.4%
- FCF Growth
- -12.9%
- 52W High
- $483.33
- 52W Low
- $282.77
- 50D MA
- $444.35
- 200D MA
- $374.76
- Beta
- 1.15
- RSI (14)
- 44
- Avg Volume
- 818.23K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Waters posted a strong third quarter with double-digit organic growth, a 21% EPS increase, and raised full-year revenue guidance on momentum in legacy Waters and improving execution in the acquired businesses.· November 3, 2026
- Organic revenue grew 10% constant currency to $871 million; total revenue was $1.767 billion and adjusted EPS rose 21% to $4.10.
- Adjusted gross margin was 55.8% and adjusted operating margin was 30.1%, helped by top-line leverage and cost actions.
- The company raised 2026 revenue guidance by $43 million at the midpoint and lifted full-year adjusted EPS guidance to $14.60-$14.70.
- Management said fourth-quarter organic growth should be 7%-9% constant currency, with days-adjusted growth stronger, and acquired businesses should also see about 10% reported growth days-adjusted.
- 2027 was framed as a step-up year, with management calling for a starting point of mid-single-digit-plus combined growth and 100 basis points of margin expansion to 29.2%.
Third quarter 2026 total company as-reported revenue was $1.767 billion. Organic revenue was $871 million, up 9% as reported and 10% in constant currency. Biosciences and Diagnostic Solutions revenue was $896 million, up 1% reported. Adjusted gross margin was 55.8% and adjusted operating margin was 30.1%. Adjusted EPS grew 21% to $4.10, while GAAP diluted EPS was $0.82. Free cash flow was $68 million, after about $81 million of BD integration, restructuring and SAP-related costs and $240 million of timing items. For 2026, management raised organic constant-currency revenue growth guidance to 9.1%-9.7%, total reported revenue to $6.479 billion-$6.497 billion, and adjusted EPS to $14.60-$14.70. Fourth-quarter 2026 guidance calls for organic constant-currency growth of 7%-9%, organic reported revenue of $984 million-$1.002 billion, Biosciences and Diagnostic Solutions revenue of about $817 million, total reported revenue of $1.801 billion-$1.819 billion, and adjusted EPS of $4.58-$4.68.
Udit Batra described the quarter as another period of "exceptional results," with strong momentum across legacy Waters and the acquired businesses. He emphasized that pricing, new products, China recovery, reshoring, and AI-related demand are building multiple growth levers, while also saying the company is well ahead of its integration and transformation plan. His tone was confident and strategic, especially around 2027, where he said Waters sees a path to higher growth and margin expansion as execution broadens.
Amol Chaubal focused on the mechanics behind the quarter and the updated guide. He cited 55.8% adjusted gross margin, 30.1% adjusted operating margin, $53 million of net interest expense, a 15.4% tax rate, and $68 million of free cash flow, noting that timing items and integration/SAP costs weighed on cash in the quarter. On guidance, he highlighted the $43 million midpoint raise to total revenue, the 2026 adjusted EPS range of $14.60-$14.70, and said the fourth-quarter guide reflects strong momentum but does not assume a budget flush. He also said 2027 margin starting assumptions include the first six weeks of BD carrying roughly a 70-basis-point margin headwind and that free cash flow should improve as one-time integration costs fade, receivables normalize, and inventory comes down from about 160 days.
Analysts pressed on what would be needed to reach the company’s 2027 high-single-digit growth ambition, and management pointed to pricing, new products, reshoring, AI, China, and semiconductors/data centers as upside levers beyond the mid-single-digit-plus starting point. On margin, Amol said the first six weeks of BD create a roughly 70-basis-point headwind next year, while Udit said the company is not changing its stepwise guidance philosophy. Questions also focused on free cash flow, where management cited heavy near-term integration and TSA-related cash drag, about $150 million of BD receivables, and elevated inventory at close to 160 days that should become a source of cash over time. In diagnostics, management said the Labcorp and Quest HPV relationships are initially about adding capacity and expanding access rather than replacing incumbents.
The call showed broad-based momentum: legacy Waters continued to grow high single digits, China improved, and acquired businesses were said to be ahead of the transformation plan. Management pointed to concrete upside levers already showing up in the numbers, including 120 basis points of pricing in the acquired businesses, strong launches like A7 and FXI, and AI-driven products that are already reducing manual work and improving reproducibility. The company also raised full-year guidance and framed 2027 as a year with multiple additional growth drivers.
Management still sees meaningful near-term complexity in the acquired businesses, including China DRG headwinds, inventory normalization, and ongoing integration costs. Cash conversion is being held back by approximately $81 million of integration/restructuring/SAP costs, $240 million of timing items, and elevated inventory levels, which Amol said are close to 160 days. The company’s 2027 framework is still a starting point rather than formal guidance, and management said it is too early to quantify the revenue contribution from AI.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.8%
- Shares Outstanding
- 98.29M
- Float Shares
- 98.10M
of shares held by institutions
1,210 13F filers
Buy/sell ratio 1.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for WAT, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Kevin HernHouse · OK01 | Sell | Aug 13, 26 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Apr 13, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Mar 10, 26 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Mar 18, 26 | Filing → |
| Thomas KeanHouse · NJ07 | Sell | Feb 13, 26 | Filing → |
| Kevin HernHouse · OK01 | — | Feb 9, 26 | Filing → |
| Debbie DingellHouse · MI06 | — | Feb 10, 26 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Oct 23, 24 | Filing → |
| Julia LetlowHouse · LA05 | Buy | Dec 8, 25 | Filing → |
| Julia LetlowHouse · LA05 | Sell | Nov 19, 24 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Sep 30, 25 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Sep 29, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 13, 25 | Filing → |
| Gilbert CisnerosHouse · CA31 | Buy | Aug 12, 25 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 8.64M | ▲ 159.54K |
| Vanguard Group Inc | 7.47M | ▼ 186.96K |
| Vanguard Capital Management LLC | 6.43M | ▲ 14.60K |
| Vanguard Portfolio Management LLC | 4.81M | ▲ 66.91K |
| State Street Corp | 4.42M | ▲ 36.20K |
| Massachusetts Financial Services Co | 4.40M | ▼ 229.90K |
| Fmr LLC | 3.75M | ▲ 2.82M |
| Invesco Ltd. | 3.33M | ▼ 166.58K |
| T. Rowe Price Investment Management, Inc. | 2.93M | ▼ 890.37K |
| Geode Capital Management, LLC | 2.66M | ▲ 22.39K |
| Alliancebernstein L.P. | 2.52M | ▼ 170.76K |
| Wellington Management Group Llp | 2.29M | ▲ 919.44K |
Held by 1,996 ETFs
Biggest fund positions in WAT by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 12, 26 | Wu Tong (NMN) | other | 2,431 |
| Nov 12, 26 | Wu Tong (NMN) | other | 1,081 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
| Oct 29, 26 | Conly D Steven | other | 0 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our WAT coverage
Recent articles, reports, and earnings notes.

Waters Corporation (WAT): BD Deal Fuels Growth, Raises Risk
Waters is leaning into a larger life-science and diagnostics platform after its BD Biosciences and Diagnostic Solutions acquisition. Strong Q1 growth and raised guidance support a Buy, but leverage and a premium valuation keep the setup balanced.

Life Sciences Tools Stocks to Own in 2026: 7 Names to Know
A seven-stock countdown spans genomics, proteomics, diagnostics, analytical tools, bioprocessing, and broad laboratory platforms.

Waters Corporation (WAT): Quality Growth Meets Integration Risk
Waters posted solid 2025 growth and enters 2026 with momentum, but the BD Biosciences & Diagnostic Solutions deal adds integration risk and a richer valuation. The stock looks like a Hold leaning to Buy on weakness as synergies and recurring revenue expansion offset execution concerns.
Want a deeper read on WAT?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
5,845 Waters Corporation $WAT Shares Acquired by Bridges Investment Management Inc.
defenseworld.net · Nov 18
Waters Corporation to Present at the 9th Annual Evercore Healthcare Conference
prnewswire.com · Nov 17
International Seaways: Even After Some Rough Waters, INSW Is Still A Buy
seekingalpha.com · Nov 17
Waters Gains FDA Clearance for Flow Cytometry Tests for Blood Cancers
zacks.com · Nov 11
Waters Achieves FDA 510(k) Clearance for Ready-to-Use Flow Cytometry Clinical Tests for Leukemia and Lymphoma
prnewswire.com · Nov 10
Waters Expands Proteomics Reach With MOBILion Systems Acquisition
zacks.com · Nov 9
Madison Mid Cap Fund Q3 2026 Portfolio Activity
seekingalpha.com · Nov 6
Jim Cramer Calls Big Tech ‘Millstones' and Names the ‘New Techs' Taking Over
247wallst.com · Nov 4
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.
AI analysis · Last refreshed November 20, 2026 · Live quote · Not investment advice